Experts discuss innovative approaches to managing Polycythemia Vera, focusing on improving patient quality of life and treatment outcomes through recent trial insights.

Experts discuss the challenges of managing fatigue and brain fog in patients with polycythemia vera, highlighting new therapies and patient support strategies.

The panel reviews current approaches to assessing thrombotic risk. Traditional models focus on age and prior thrombosis history, which provide a foundation for clinical decisions. However, they emphasize that these criteria may not fully capture individual patient risk.

Experts discuss the place of ruxolitinib for patients with PV resistant or intolerant to hydroxyurea. They note that ruxolitinib can offer durable symptom control and improve hematologic parameters. Benefits include reduction in spleen size, symptomatic relief, and improved quality of life metrics documented in clinical trials. Limitations include potential adverse effects such as weight gain, lipid changes, and infection risk.

This section examines how emerging agents such as rusfertide and givinostat may reshape the polycythemia vera treatment paradigm.

In this segment the panel challenges the long standing focus on maintaining hematocrit below forty five percent as the sole marker of disease control.

This section provides a balanced overview of currently approved treatments for polycythemia vera, including phlebotomy, hydroxyurea, and interferon.

In this section, the panel examines how clinical trials and emerging molecular insights may shape the future of polycythemia vera management.

In the closing segment the faculty reflect on polycythemia vera as a field undergoing meaningful change. Emerging therapies offer opportunities to reduce treatment burden, improve symptom control, and enhance quality of life.